Association of salvage radiotherapy with survival outcomes in extracranial oligoprogression after first-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective cohort study.
Аннотация
BACKGROUND
While first-line systemic therapy is the standard of care for extensive-stage small-cell lung cancer (ES-SCLC), therapeutic failure remains nearly universal, with survival heavily dictated by progression patterns. Extracranial oligoprogression represents a distinct treatment failure phenotype lacking standardized management.
OBJECTIVES
To evaluate the efficacy and survival impact of salvage radiotherapy (RT) in ES-SCLC patients experiencing extracranial oligoprogression after first-line therapy.
DESIGN
A multicenter retrospective cohort study.
METHODS
We retrospectively enrolled patients with ES-SCLC developing extracranial oligoprogression after first-line therapy from three cancer centers in China between January 2020 and March 2025. Patients were stratified into RT and non-RT groups based on the administration of radiotherapy post-progression. Propensity score matching (PSM) was employed to balance baseline characteristics. Primary endpoints included second-line overall survival (OS2) and progression-free survival (PFS2), estimated via Kaplan-Meier analysis and compared using log-rank tests.
RESULTS
A total of 232 Chinese patients experienced extracranial oligoprogression, with a median time to progression of 6.1 months (range: 1.0-37.8 months). In the matched cohort, RT significantly prolonged median PFS2 (6.1 vs 3.3 months; p = 0.007) and OS2 (13.4 vs 8.4 months; p = 0.029). Subgroup analyses revealed more pronounced survival benefits in patients characterized by prior immunotherapy, progression of existing lesions, intrathoracic progression, and delayed progression (PFS1 >6 months). Furthermore, among patients who received RT, continuation of first-line systemic therapy was associated with superior PFS2 (9.6 vs 5.4 months; p = 0.017) and OS2 (14.4 vs 13.4 months; p = 0.030) compared with switching to an alternative systemic therapy.
CONCLUSION
This multicenter study is one of the first to indicate that radiotherapy is associated with a survival benefit in patients with ES-SCLC and extracranial oligoprogression. Notably, combining radiotherapy with continuation of first-line systemic therapy offered greater clinical utility than switching to an alternative systemic therapy.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.